The Global Automated Cell Counters Market is estimated to be valued at US$ 3.75 billion in 2023 and is expected to exhibit a CAGR of 7% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Automated cell counters are devices used to count and analyze cells in biological samples. These devices have various applications in research, drug discovery, diagnostics, and regenerative medicine. They provide accurate and rapid cell counts, reducing the time and effort required for manual cell counting. Automated cell counters have become an essential tool in cancer research, allowing researchers to monitor cell growth, apoptosis, and drug response. They are also widely used in pharmaceutical and biotechnology companies for quality control and cell-based assays.
Key Takeaways:
The global automated cell counters market is expected to witness high growth, exhibiting a CAGR of 7% over the forecast period of 2023 to 2030. This growth is driven by the increasing adoption of automated cell counters in research and diagnostic laboratories for quick and accurate cell counting. The Asia-Pacific region is expected to be the fastest-growing and dominating region in the market, attributed to the rising demand for improved healthcare infrastructure and increasing investments in research and development in countries like China and India. Key players operating in the automated cell counters market include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer Inc., Bio-Rad Laboratories, BD, Merck KGaA, Logos Biosystems, Corning Incorporated, Tecan, and Sartorius AG.
Read More:
